Floatz logo

Tivozanib

Stage II Renal Pelvis Cancer AJCC v8

Alliance for Clinical Trials in OncologySmall moleculePhase 3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Stage II Renal Pelvis Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
H. Lee Moffitt Cancer Center and Research Institute
Phase 3BB
Vinflunine
Dr Anders Ullén
Phase 2BB
Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3B
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Eli Lilly and Company
Phase 2B
Icrucumab
Eli Lilly and Company
Phase 2B

View all 17 →

Same molecule, other indications

Tivozanib is also rated in:

renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →